Jean-Yves PIERGA
Institut Curie · Institut Curie Paris · Institut Curie, Paris, France
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jean-Yves PIERGA as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:04 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07661927 · Skipping Hormone Therapy in Low-Risk Early Breast CancerUNICANCER · recruiting · Breast Cancer (Early Breast Cancer) · principal investigator
- Ph2NCT05973864 · Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and SurgeryUNICANCER · recruiting · Triple Negative Breast Neoplasms · principal investigator
- N/ANCT02608346 · Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)Institut Curie · completed · Women With BRCA1 Germline Deleterious Mutation · principal investigator
- N/ANCT02220556 · Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral PathologyInstitut Curie · completed · Solid Tumor, Adult · principal investigator
- N/ANCT01745757 · Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast CancerUNICANCER · completed · Metastatic, Breast Cancer · principal investigator
- Ph3NCT01710605 · Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast CancersInstitut Curie · unknown · Ductal Infiltrating Metastatic Breast Cancer, Hormone-receptors Positive Breast Cancer · principal investigator
- Ph2NCT01548677 · Efficacy Study of Herceptin to Treat HER2-negative CTC Breast CancerEuropean Organisation for Research and Treatment of Cancer - EORTC · completed · Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Circulating Tumor Cells · study chair
- Ph3NCT01180335 · Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast CancerGustave Roussy, Cancer Campus, Grand Paris · completed · Breast Cancer · principal investigator
- N/ANCT00898014 · Blood Levels of Tumor Cells in Predicting Response in Patients Receiving First-Line Chemotherapy for Stage IV Breast CancerInstitut Curie · completed · Breast Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:04 UTC. The ranking covers the 200 most relevant of 74 PubMed records, and a shared surname and initials can bring in a namesake. All 74 on PubMed
- 2,392 citationsRCR 180.8
- 1,456 citationsRCR 45.6
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.N Engl J Med · 2021778 citationsRCR 43.5
- Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.Lancet Oncol · 2013597 citationsRCR 16.2
- Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.N Engl J Med · 2024478 citationsRCR 61.6
- 344 citationsRCR 9.8
- 327 citationsRCR 20.7
- 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.Lancet Oncol · 2021285 citationsRCR 14.9
- 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.Lancet Oncol · 2013245 citationsRCR 6.1
- 225 citationsRCR 5.8